CAR-T therapy brings new approach to multiple myeloma treatment

Tern plc

CAR-T cell therapy is providing a different approach to treating multiple myeloma by using genetically modified immune cells to recognise and attack cancer cells.

The treatment takes T cells from a patient’s own immune system and modifies them so they can identify a specific target on cancer cells. The cells are then multiplied and returned to the patient, where they can seek out and attack the targeted cells.

Multiple myeloma is a cancer of plasma cells and can become difficult to treat after several previous therapies. CAR-T therapy has therefore emerged as an additional treatment option for some patients whose disease has returned or stopped responding to previous treatments.

The approach differs from conventional drug treatment because the therapeutic agent is made from the patient’s own immune cells. Rather than introducing a medicine designed to attack cancer cells directly, CAR-T modifies T cells to recognise a specific target associated with the cancer.

Clinical studies have reported responses among patients with relapsed or refractory multiple myeloma who have received multiple previous treatments. Two BCMA-directed CAR-T therapies, idecabtagene vicleucel and ciltacabtagene autoleucel, have demonstrated significant activity in this setting. Further studies have also examined their use at earlier stages of treatment.

Research is now moving beyond the use of CAR-T therapy in heavily pre-treated patients. Clinical trials have investigated whether the treatment can be used earlier in the course of multiple myeloma, when patients may have healthier T cells and lower levels of disease.

Randomised trials have reported improved progression-free survival for CAR-T therapies compared with standard treatment in certain second- and third-line multiple myeloma populations. This has increased research interest in moving CAR-T treatment further towards earlier lines of therapy.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Tern invests £78,000 in Device Authority through 8% convertible loan notes

Tern Plc has committed approximately £78,000 to new convertible loan notes issued by Device Authority, which carry 8% annual...

Search